Navigation Links
ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Date:10/10/2007

SAN DIEGO, Oct. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has completed patient enrollment in its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion), a novel, emulsion formulation of vinorelbine tartrate. Vinorelbine tartrate, marketed under the brand name Navelbine(R), is an anti-cancer agent that is approved to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million.

"Completing enrollment keeps us on schedule to announce results from this study next month and, if the results are succesful, to submit an NDA as early as next year," said Evan M. Levine, chief executive officer of ADVENTRX. "Advancing ANX-530 is a key value-driver for this company and we are taking the steps to help ensure its success. We are preparing for a meeting with the FDA later this year and plan to provide an update regarding our NDA timeline for ANX-530 following that meeting."

ANX-530 is currently being tested in a 28-patient bioequivalence study. The study is a crossover comparison of ANX-530 and Navelbine, also available as generic vinorelbine, with a primary endpoint of pharmacokinetic equivalence of ANX-530 and Navelbine. The safety of a single dose of ANX-530 is being evaluated as a secondary endpoint. The FDA has indicated that this single clinical study, should it demonstrate bioequivalence between ANX-530 and Navelbine, would provide sufficient clinical dat
'/>"/>

SOURCE ADVENTRX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. Adventrx Announces Positive Data From Multidrug Therapy With CoFactor
3. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 1, 2012  Ultragenyx Pharmaceutical Inc., a biotechnology company ... genetic disorders, today announced results from a first-in-human, ... with hereditary inclusion body myopathy (HIBM) showing that ... profile on absorption after oral administration.  UX001 is ...
... (OTC Bulletin Board: NWBO ) (NW Bio) today announced ... received approval of a major grant from the Sachsische Aufbau ... will reimburse fifty percent (50%) of the costs for manufacturing ... for brain cancer at up to ...
Cached Medicine Technology:Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 2Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 3Northwest Bio Awarded $5.5 Million German Government Grant 2Northwest Bio Awarded $5.5 Million German Government Grant 3Northwest Bio Awarded $5.5 Million German Government Grant 4
(Date:12/24/2014)... (PRWEB) December 24, 2014 Connie Casad, ... and functional medicine advocate with 30 years of practice ... to evaluate the health benefits of dietary detoxification. The ... new participants following excellent results from test patients who ... asked to explain her interest in conducting the study, ...
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
(Date:12/24/2014)... 2014 BambooIndustry.com a famous bamboo flooring ... Today, the company announces its multiple layer bamboo ... on these new products. , Bamboo panel is the ... multiple layer bamboo panel board features high quality selective ... emissions free. The bamboo panel consists of multiple layers ...
(Date:12/24/2014)... 2014 (HealthDay News) -- Adults who experienced childhood ... migraine headaches, suggests a study published online Dec. ... "Childhood maltreatment can have long-lasting effects, like associated ... study author Dawn Buse, director of behavioral medicine ... said in a journal news release. "When ...
(Date:12/24/2014)... 24, 2014 Gluten, a protein found ... who have an intolerance to gluten, causing side effects ... migraine headaches, joint pain and fatigue. For this reason, ... that deliver safe and fast weight loss while ... a gluten allergy reaction. These gluten free diet plans ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... , PITTSBURGH, Sept. 22 Precision Therapeutics today ... received the Smart Business Magazine 2009 Pacesetters Award. This ... area who are setting the pace for the region. ... of their influence in the community-at-large as well as within ...
... , , ... CutisPharma, Inc. announced the introduction of FIRST(R) - BXN Mouthwash. ... line, which already includes FIRST(R) - Mouthwash BLM. The active ... in the most routinely prepared formulation of Magic Mouthwash containing Benadryl(R), ...
... , , AUSTIN, ... pleased to announce its selection to participate in DEMO conference,s ... features the "coolest, earliest-stage companies." Ringful will launch a mobile ... mobile phone into a connected personal healthcare dashboard, resulting in ...
... Twin ... for 10-city whirlwind tour of Japan to change hearts and minds about the benefits ... , ... (PRWEB) September 22, 2009 -- Twin Triumph Productions, LLC announced today that Academy Award ...
... ATLANTA, Sept. 22 Atlanta Falcons Defensive End Chauncey ... Follmer and Camp Kudzu- Georgia,s largest camp for kids with ... Blank Family Office. , , Davis was ... and Jonathan Babineaux, corporate executives and community leaders during the ...
... research is too focused on new drug development, while not ... advances in knowledge likely to have the biggest impact on ... research policy expert says, adding that a major shift in ... with the coming wave of cancer cases. Professor Richard ...
Cached Medicine News:Health News:Precision Therapeutics President and CEO Sean McDonald Recipient of 2009 Pacesetters Award 2Health News:CutisPharma Launches New Prescription Mouthwash Kit Adding to Product Line 2Health News:Ringful Selected for DEMO's AlphaPitch; Launching PreventiveCare.mobi Healthcare Application Suite 2Health News:Twin Triumph Productions and 'The Power of Two' Go to Japan 2Health News:Twin Triumph Productions and 'The Power of Two' Go to Japan 3Health News:Atlanta Falcons Chauncey Davis Honors 2009 Community Impact Awardees 2Health News:Expert calls for new cancer research priorities 2Health News:Expert calls for new cancer research priorities 3
... The new HF35-50 High Frequency Ultrasound ... high resolution, high frequency system available. The ... ultrasound biomicroscopy of the anterior segment with ... posterior segment ultrasound with a 20 MHz ...
... portable, digital A-scan system which provides easy-to-use ... high frequency, low noise probe and fast ... application of the probe along the visual ... display, storage of 5 different user profiles, ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... In addition to three conventional measurement modes ... also incorporates a new axial length measuring ... by calculating sonic velocity for conversion at ... length by calculating each tissues sonic velocity ...
Medicine Products: